NCT04380545View on ClinicalTrials.gov

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Unresectable Fibrolamellar Carcinoma
Interventions
DRUG

Fluorouracil

Given IV

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Recombinant Interferon Alpha 2b-like Protein

Given SC

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER